Genitourinary-Cancer-Meeting
Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
179 0 Acute Lymphoblastic Leukemia Free
Trending
Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16
Avelumab tolerable for patients according to JAVELIN Solid Tumor phase Ib trial
Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Subgroup analyses of METEOR
CheckMate 025 phase III trial
Immunotherapy in non muscle invasive bladder cancer #GU16
How soon should we expect approval of immunotherapy in urothelial cancer #GU16
Future role of immunotherapy and checkpoint inhibitors in urothelial cancer #GU16
Atezolizumab shows very significant activity in advanced urothelial cancer #GU16
My videos
Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group at the 2018 ASCO.
179 Views
2 years ago
Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16
Clinical and pathological factors that can influence outcomes in upper tract urothelial cancer #GU16
Annual Meeting GU 2016 Role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer
Annual Meeting GU 2016 Immune checkpoint inhibitors in combination with chemotherapy or targeted agents for urothelial cancers
Annual Meeting GU 2016 Clinical trials in bladder cancer with Atezolizumab and Pembrolizumab
Annual Meeting GU 2016 Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced bladder cancer
Annual Meeting GU 2016 Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer
Recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer Annual Meeting GU 2016
Ongoing clinical trials that will establish a clinical role for molecular risk factors in prostate cancer
Molecular markers that have been identified in prognosis and risk of relapse in localized prostate cancer.
